TG-1801
A Phase 1 First-in-Human Study of Bispecific Antibody TG-1801 in Subjects With B-Cell Lymphoma
Disease:
B-Cell Lymphoma
Summary:
Patients with relapsed or refractory B-Cell Lymphoma will receive weekly infusions of TG-1801 for the first 2 cycles (2 months) and then monthly infusions, for a total of 6 months maximum treatment
Eligibility:
Include, but not limited to, the following:
Inclusion criteria: Exclusion Criteria:
1. Patients must be 18 years or over
2. Relapsed or refractory B-Cell Lymphoma
3. Measurable disease and adequate organ function (as specified in the protocol)
4. No other active cancers
5. No other major health problems
1. Subjects receiving cancer therapy or investigational drug within 21 days of Cycle 1 Day
2. Prior autologous stem cell transplant within 6 months
3. Active Hepatitis B or Hepatitis C
Contact person:
Lewis Edwards
Email cancertrialshaem1@linear.org.au
Phone 08 9386 5125
Principal Investigator:
A/Prof Chan Cheah
08 6457 7600
Sponsor:
TG Therapeutics, Inc
Phase:
1
Protocol Number:
TG-1801-101
Trial Registration Number:
NCT03804996
Kobe Creations